This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diggle, C. P. Articles by Harnden, P. Search for Related Content PubMed PubMed Citation Articles by Diggle, C. P. Articles by Harnden, P.

(American Journal of Pathology. 2003;163:493-504.)
© 2003 American Society for Investigative Pathology

Identification of Genes Up-Regulated in Urothelial Tumors

The 67-kd Laminin Receptor and Tumor-Associated Trypsin Inhibitor

Christine P. Diggle^*, Sheena Cruickshank^*, Jonathon D. Olsburgh^*, Stephanie Pellegrin^*, Barbara Smith, Rosamonde E. Banks^*, Peter J. Selby^*, Margaret A. Knowles^*, Jennifer Southgate and Patricia Harnden^*

From the Cancer Research United Kingdom Clinical Centre,^* St. James’s University Hospital, Leeds; and the Department of Biology, Jack Birch Unit of Molecular Carcinogenesis, University of York, York, United Kingdom

Studies investigating changes in gene expression in urothelial carcinoma have generally compared tumors of different stages and grades but comparisons between low-grade, noninvasive tumors and normal urothelium are needed to identify genes involved in early tumor development. We isolated the urothelium from a low-grade tumor and corresponding normal mucosa by laser capture microdissection on frozen sections. The RNA extracted was amplified to generate suppressive subtractive cDNA libraries. Random sequencing of cDNA clones identified 100 unique species. Of these 83% were known genes, 15% had homology to genes with an unknown function in humans, and 2% did not show homology to any published gene sequence. Two of the known genes, the 67-kd laminin receptor (67LR) and tumor-associated trypsin inhibitor (TATI), had previously been associated with metastatic progression in many tumor types, although 67LR has not been investigated in urothelial tumors. Immunolabeling of the original tissue with antibodies against these two genes confirmed overexpression, validating our strategy: 67LR was not expressed in the normal urothelium but was present in the tumor, whereas TATI expression was confined to umbrella cells in the normal urothelium, but extended to all cell layers in the tumor. We investigated both markers further in a separate series of tumors of different stages and grades. TATI was more consistently overexpressed than 67LR in all tumor grades and stages. Levels of secreted TATI were significantly higher in urine samples from patients with tumors compared to controls. Our strategy, combining laser capture microdissection and cDNA library construction, has identified genes that may be involved in the early phases of urothelial tumor development rather than with disease progression, highlighting the importance of comparing tumor with normal rather than just tumors of different stages and grades.

This article has been cited by other articles:

				J. W. Gillespie, G. Gannot, M. A. Tangrea, M. Ahram, C. J.M. Best, V. E. Bichsel, E. F. Petricoin, M. R. Emmert-Buck, and R. F. Chuaqui Molecular Profiling of Cancer Toxicol Pathol, January 1, 2004; 32(1_suppl): 67 - 71. [Abstract] [PDF]